The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early huntington disease

JAMA Neurology

Volumn 71, Issue 12, 2014, Pages 1520-1528

  Russell, David S ^a,b   Barret, Olivier ^a,b   Jennings, Danna L ^a,b   Friedman, Joseph H ^c   Tamagnan, Gilles D ^a,b   Thomae, David ^a,b,d   Alagille, David ^a,b   Morley, Thomas J ^a,b   Papin, Caroline ^a,b   Papapetropoulos, Spyridon ^e   Waterhouse, Rikki N ^e   Seibyl, John P ^a,b   Marek, Kenneth L ^a,b  

^a INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

^b Molecular NeuroImaging LLC   (United States)

^c BROWN UNIVERSITY   (United States)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 [3 [4 (2 FLUOROETHOXY)PHENYL] 7 METHYL 4 OXO 3,4 DIHYDROQUINAZOLIN 2 YL]ETHYL] 4 ISOPROPOXYISOINDOLINE 1,3 DIONE F 18; BIOLOGICAL MARKER; TRACER; UNCLASSIFIED DRUG; FLUORINE; PHOSPHODIESTERASE;

ADULT; AGED; ARTICLE; BASAL GANGLION; BINDING KINETICS; BINDING POTENTIAL; BRAIN ATROPHY; CLINICAL ARTICLE; COHORT ANALYSIS; CORRELATIONAL STUDY; DISEASE SEVERITY; FEMALE; HEADACHE; HEREDITY; HUMAN; HUNTINGTON CHOREA; ISOTOPE LABELING; MALE; MIDDLE AGED; MOTOR SUBSCALE SCORE; NAUSEA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; RELIABILITY; SCORING SYSTEM; UNIFIED HUNTINGTON DISEASE RATING SCALE; YOUNG ADULT; CORPUS STRIATUM; DIAGNOSTIC USE; EARLY DIAGNOSIS; EVALUATION STUDY; METABOLISM; PATHOPHYSIOLOGY; PROCEDURES; SCINTISCANNING; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; BIOLOGICAL MARKERS; CORPUS STRIATUM; EARLY DIAGNOSIS; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; PHOSPHORIC DIESTER HYDROLASES; POSITRON-EMISSION TOMOGRAPHY; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84918559868     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.1954     Document Type: Article

References (61)

1. Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10(1):83-98.
2. Seibyl J, Russell D, Jennings D, Marek K. Neuroimaging over the course of Parkinson's disease: from early detection of the at-risk patient to improving pharmacotherapy of later-stage disease. Semin Nucl Med. 2012;42(6):406-414.
3. Jack CR Jr, Knopman DS, JagustWJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207-216.
4. van den Bogaard S, Dumas E, van der Grond J, van Buchem M, Roos R. MRI biomarkers in Huntington's disease. Front Biosci (Elite Ed). 2012;4:1910-1925.
5. Tabrizi SJ, Langbehn DR, Leavitt BR, et al; TRACK-HD investigators. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009;8(9):791-801.
6. Paulsen JS. Functional imaging in Huntington's disease. Exp Neurol. 2009;216(2):272-277.
7. Lakics V, Karran EH, Boess FG. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology. 2010;59(6):367-374.
8. Xie Z, AdamowiczWO, EldredWD, et al. Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase. Neuroscience. 2006;139(2):597-607.
9. Seeger TF, Bartlett B, Coskran TM, et al. Immunohistochemical localization of PDE10A in the rat brain. Brain Res. 2003;985(2):113-126.
10. Coskran TM, Morton D, Menniti FS, et al. Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J Histochem Cytochem. 2006;54(11):1205-1213.
11. Francis SH, Blount MA, Corbin JD. Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev. 2011;91(2):651-690.
12. Kleppisch T. Phosphodiesterases in the central nervous system. In: Schmidt HHHW, Hofmann F, Stasch J-P, eds. cGMP: Generators, Effectors and Therapeutic Implications. Berlin, Germany: Springer; 2009:71-92.
13. Surapisitchat J, Beavo JA, Ralph AB, Edward AD. Phosphodiesterase Families: Handbook of Cell Signaling. 2nd ed. San Diego, CA: Academic Press; 2010:1409-1414.
14. ContiM, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem. 2007;76(1):481-511.
15. Nishi A, KuroiwaM,Miller DB, et al. Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J Neurosci. 2008;28(42):10460-10471.
16. 1 receptor signaling in striatal neurons. Front Neuroanat. 2011;5:43. doi: 10.3389/fnana.2011.00043.
17. Wallace TL, Ballard TM, Pouzet B, RiedelWJ, Wettstein JG. Drug targets for cognitive enhancement in neuropsychiatric disorders. Pharmacol Biochem Behav. 2011;99(2):130-145.
18. Kleiman RJ, Kimmel LH, Bove SE, et al. Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease. J Pharmacol Exp Ther. 2011;336(1):64-76.
19. Grauer SM, Pulito VL, Navarra RL, et al. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther. 2009;331(2):574-590.
20. Chappie TA, Helal CJ, Hou X. Current landscape of phosphodiesterase 10A (PDE10A) inhibition. J Med Chem. 2012;55(17):7299-7331.
21. Giampà C, Laurenti D, Anzilotti S, Bernardi G, Menniti FS, Fusco FR. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease. PLoS One. 2010;5(10): e13417. doi:10.1371/journal.pone.0013417.
22. Reiner A, Albin RL, Anderson KD, D'Amato CJ, Penney JB, Young AB. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A. 1988;85(15):5733-5737.
23. Albin RL, Reiner A, Anderson KD, et al. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann Neurol. 1992;31(4):425-430.
24. Aylward EH, Codori AM, Rosenblatt A, et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Mov Disord. 2000;15(3):552-560.
25. Aylward EH, Sparks BF, Field KM, et al. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology. 2004;63(1):66-72.
26. van den Bogaard SJ, Dumas EM, Acharya TP, et al TRACK-HD Investigator Group. Early atrophy of pallidum and accumbens nucleus in Huntington's disease. J Neurol. 2011;258(3):412-420.
27. Henley SMD,Wild EJ, Hobbs NZ, et al. Relationship between CAG repeat length and brain volume in premanifest and early Huntington's disease. J Neurol. 2009;256(2):203-212.
28. Menalled L, Zanjani H, MacKenzie L, et al. Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease. Exp Neurol. 2000;162(2):328-342.
29. Menalled LB, Kudwa AE, Miller S, et al. Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175. PLoS One. 2012;7(12): e49838. doi:10.1371/journal.pone.0049838.
30. Hebb ALO, Robertson HA, Denovan-Wright EM. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenicmice prior to the onset of motor symptoms. Neuroscience. 2004;123(4):967-981.
31. Hu H,McCaw EA, Hebb ALO, Gomez GT, Denovan-Wright EM. Mutant huntingtin affects the rate of transcription of striatum-specific isoforms of phosphodiesterase 10A. Eur J Neurosci. 2004;20(12):3351-3363.
32. Rising AC, Xu J, Carlson A, Napoli VV, Denovan-Wright EM, Mandel RJ. Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats. Exp Neurol. 2011;228(2):173-182.
33. Desplats PA, Kass KE, Gilmartin T, et al. Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. J Neurochem. 2006;96(3):743-757.
34. 18F]MNI-654. J Nucl Med. 2014;55(8):1297-1304.
35. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord. 1996;11(2):136-142.
36. Shoulson I, Fahn S. Huntington disease: clinical care and evaluation. Neurology. 1979;29(1):1-3.
37. Marder K, Zhao H, Myers RH, et al Huntington Study Group. Rate of functional decline in Huntington's disease. Neurology. 2000;54(2):452-458.
38. Tabrizi SJ, Scahill RI, Owen G, et al TRACK-HD Investigators. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol. 2013;12(7):637-649.
39. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR; International Huntington's Disease Collaborative Group. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet. 2004;65(4):267-277.
40. Penney JB Jr, Vonsattel J-P, MacDonald ME, Gusella JF, Myers RH. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol. 1997;41(5):689-692.
41. 18F-JNJ41510417 as a radioligand for PET imaging of phosphodiesterase-10A in the brain. J Nucl Med. 2010;51(10):1584-1591.
42. Hobbs NZ, Barnes J, Frost C, et al. Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study. AJNR Am J Neuroradiol. 2010;31(6):1036-1041.
43. van Oostrom JC, Maguire RP, Verschuuren-Bemelmans CC, et al. Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease. Neurology. 2005;65(6):941-943.
44. Georgiou-Karistianis N, Scahill R, Tabrizi SJ, Squitieri F, Aylward E. Structural MRI in Huntington's disease and recommendations for its potential use in clinical trials. Neurosci Biobehav Rev. 2013;37(3):480-490.
45. Weir DW, Sturrock A, Leavitt BR. Development of biomarkers for Huntington's disease. Lancet Neurol. 2011;10(6):573-590.
46. Kipps CM, Duggins AJ, Mahant N, Gomes L, Ashburner J, McCusker EA. Progression of structural neuropathology in preclinical Huntington's disease: a tensor based morphometry study. J Neurol Neurosurg Psychiatry. 2005;76(5):650-655.
47. Versluis MJ, van der Grond J, van Buchem MA, van Zijl P,Webb AG. High-field imaging of neurodegenerative diseases. Neuroimaging Clin N Am. 2012;22(2):159-171.
48. 11C]Raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length. Ann Neurol. 1998;43 (2):253-255.
49. 2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann Neurol. 1996;40(1):49-54.
50. Ciarmiello A, Cannella M, Lastoria S, et al. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J Nucl Med. 2006;47(2):215-222.
51. 123I]omazenil and SPECT. J Neurol Neurosurg Psychiatry. 2001;70(5):657-661.
52. van Oostrom JCH, Dekker M, Willemsen ATM, de Jong BM, Roos RAC, Leenders KL. Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease. Eur J Neurol. 2009;16(2):226-231.
53. Feigin A, Tang C, Ma Y, et al. Thalamic metabolism and symptom onset in preclinical Huntington's disease. Brain. 2007;130(Pt 11):2858-2867.
54. Kieburtz K, Venuto C. TRACK-HD: both promise and disappointment. Lancet Neurol. 2012;11(1):24-25.
55. Cha J-HJ. Transcriptional signatures in Huntington's disease. Prog Neurobiol. 2007;83(4):228-248.
56. Seredenina T, Luthi-Carter R. What have we learned from gene expression profiles in Huntington's disease? Neurobiol Dis. 2012;45(1):83-98.
57. Savas JN, Ma B, Deinhardt K, et al. A role for Huntington disease protein in dendritic RNA granules. J Biol Chem. 2010;285(17):13142-13153.
58. Sugars KL, Brown R, Cook LJ, Swartz J, Rubinsztein DC. Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis. J Biol Chem. 2004;279(6):4988-4999.
59. Shimohata T, Nakajima T, Yamada M, et al. Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat Genet. 2000;26(1):29-36.
60. Nucifora FC Jr, Sasaki M, Peters MF, et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science. 2001;291(5512):2423-2428.
61. Ahmad R, Bourgeois S, Postnov A, et al. PET imaging shows loss of striatal PDE10A in patients with Huntington disease. Neurology. 2014;82(3):279-281.